Evusheld and Paxlovid

Background

Evusheld (long-acting antibody) and Paxlovid (antiviral) are being evaluated together to neutralize SARS-CoV-2 and prevent viral replication in long COVID cases.

Mechanism of Action

1. Evusheld: Provides long-term viral neutralization (Evusheld Factsheet). The Fc effector function has been muted on this molecule, which some believe reduces side effects like ADE.
2. Paxlovid: Inhibits viral replication (Paxlovid Factsheet).

Pros and Cons

• Pros: Combines immune protection with viral replication inhibition; both drugs were FDA-approved.
• Cons: Evusheld lost its FDA EUA when variants mutated, and unclear if Astrazeneca is interested in this indication or clinical trials. Paxlovid has significant drug interactions.

References

1. Evusheld Factsheet
2. Paxlovid Factsheet

‍